Previous studies have shown that Src kinase inhibitors can induce NSCLC cell apoptosis and inhibit angiogenesis and, depending on the EGFR mutation status, EGFR tyrosine kinase activation [17, 18]. Here, EGFR is linked to non-small cell lung carcinoma.